Search results
Results From The WOW.Com Content Network
The £490 million contract for the NRTS was awarded to the GeneSYS Consortium on 19 September 2005. GeneSYS Consortium is a group of companies led by the Fluor Corporation and is a Public–private partnership. The system is designed to allow a national scheme of road pricing, possibly using radio-frequency identification tags. [1]
In 1949, the federal research facility was established as the National Reactor Testing Station (NRTS). [5] In 1975, the United States Atomic Energy Commission (AEC) was divided into the Energy Research and Development Administration (ERDA) and the Nuclear Regulatory Commission (NRC).
Stationary Low-Power Reactor Number One, also known as SL-1, initially the Argonne Low Power Reactor (ALPR), was a United States Army experimental nuclear reactor in the western United States at the National Reactor Testing Station (NRTS) in Idaho about forty miles (65 km) west of Idaho Falls, now the Idaho National Laboratory.
In 1949, the Atomic Energy Commission opened the National Reactor Testing Station (NRTS) in the desert west of Idaho Falls. On December 20, 1951, a nuclear reactor there produced useful electricity for the first time in history. There have been more than 50 unique reactors built at the facility for testing—only three remain active.
Combining NRTs can also increase quit-success rates by up to 25% compared to using them alone, based on a Cochrane systematic review by Lindson, et al., on combination therapy for fast-acting ...
NRTS made further history on January 3, 1961, when the SL-1 reactor was destroyed through an operator maintenance error, with the ensuing steam explosion causing the deaths of all three personnel present. It was the world's first and the United States' only fatal reactor accident.
Nicotine replacement therapy (NRT) is a medically approved way to treat people with tobacco use disorder by taking nicotine through means other than tobacco. [6] It is used to help with quitting smoking or stopping chewing tobacco.
Nucleoside analog reverse-transcriptase inhibitors (NARTIs or NRTIs) compose the first class of antiretroviral drugs developed. In order to be incorporated into the viral DNA, NRTIs must be activated in the cell by the addition of three phosphate groups to their deoxyribose moiety, to form NRTI triphosphates.